NCT06864884 A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction
| NCT ID | NCT06864884 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Arcato Laboratories, Inc. |
| Condition | Acute Post Operative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-02-26 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-02-26 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side effects?
Eligibility Criteria
Inclusion Criteria: * Able to provide informed consent * In generally good health * BMI 18 to 38kg/m² * Scheduled to undergo wisdom teeth extraction Exclusion Criteria: * Serious medical condition * Clinically significant abnormal lab values * Blood donation in the last 60 days, or plasma donation in the last 7 days.
Frequently Asked Questions
Who can join the NCT06864884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Acute Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06864884 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06864884 currently recruiting?
Yes, NCT06864884 is actively recruiting participants. Visit ClinicalTrials.gov or contact Arcato Laboratories, Inc. to inquire about joining.
Where is the NCT06864884 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT06864884 clinical trial?
NCT06864884 is sponsored by Arcato Laboratories, Inc.. The trial plans to enroll 30 participants.